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A Pervasive Pathogen Highlights the need for
new Antimicrobial development
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Staphylococcus aureus (S. aureus) has entered the spotlight as a globally pervasive drug-
resistant pathogen. while historically associated exclusively with hospital-acquired infec-
tions in immunocompromised hosts, the methicillin-resistant form of S. aureus has been
spreading throughout communities since the 1990s. Indeed, it has now become a common
household term: MRSA. S. aureus has developed numerous mechanisms of virulence and
strategies to evade the human immune system, including a host of surface proteins, se-
creted enzymes, and toxins. In hospital intensive care units, the proportion of MRSA-related
S. aureus infections has increased strikingly from just 2 percent in 1974 to 64 percent in
2004. Its presence in the community has been rising similarly, posing a significant public
health burden. The growing incidence of MRSA unfortunately has been met with dwindling
efforts to develop new, more effective antibiotics. The continued emergence of resistant
strains of bacteria such as MRSA demands an urgent revival of the search for new antibi-
otics.
introduction
Infectious  diseases  are  the  second
leading cause of death worldwide and the
third leading cause of death in developed
countries  [1]. The  rapid  emergence  and
spread of drug-resistant organisms, such as
Staphylococcus aureus (S. aureus), both in
the healthcare setting and the community
prompts great urgency in the development
of and advocacy for prevention and treat-
ment efforts.
S. aureus, a Gram-positive bacterium,
is both a commensal organism found as
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of the population as well as a resourceful
human pathogen able to cause severe and
devastating illness [2] (Figure 1). The pre-
cipitous  spread  of  methicillin-resistant
strains of S. aureus (MRSA) ― a so-called
“superbug” ― has created new challenges
for governments, healthcare systems, and
drug development. From skin abscess and
cellulitis to invasive bacteremia, endocardi-
tis, and septic arthritis, MRSA is capable of
causing significant human disease [3]. Once
thought of as a hospital-acquired infection
of immunocomprised hosts, MRSA found
its way out of the hospitals and into com-
munities,  infecting  individuals  with  no
known risk factors. The sudden develop-
ment and spread of antibiotic-resistant bac-
teria  such  as  MRSA,  coupled  with  a
dwindling culture of antibiotic research and
development, sets the stage for a bold mul-
tidisciplinary campaign called the 10x‘20
initiative to  reinvigorate  the  antibiotic
pipeline. In this review, we describe the
pathogenesis of S. aureus-related illness,
discuss common mechanisms of resistance
to methicillin, and highlight the necessity for
developing novel antibiotic therapies. 
S. AureuS: PAtHogeneSiS And
Virulence FActorS
A critical first step in the pathogenesis
of  S.  aureus infection  is  colonization.
Asymptomatic colonized individuals pro-
vide a reservoir for the human-to-human
spread of disease. The primary modes of
transmission include direct skin-to-skin con-
tact with a colonized source and, to a lesser
extent, contact with colonized fomites [4].
Disruption of the normal skin barrier (e.g.,
abrasion, burn) as well as immunosuppres-
sive conditions (e.g., HIV, steroid use, ge-
netic diseases) predispose colonized hosts to
infection [5].
A plethora of surface proteins and se-
creted virulence factors endow S. aureus
with great potential to cause disease (Figure
2). Understanding the detailed mechanisms
by which these factors cause S. aureus-re-
lated illness provides opportunities to de-
velop targeted therapeutics.
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Figure 1. Scanning electron micrograph of a cluster of Staphylococcus aureus.
Image obtained from the Public Health Image Library of the Centers for Disease Control
and Prevention (Janice Carr) (http://phil.cdc.gov/Phil/default.asp).Surface Proteins
To initiate infection, S. aureus must first
adhere to host tissues or prosthetic devices.
To accomplish this, S. aureus uses a con-
stellation of surface proteins known as mi-
crobial  surface  components  recognizing
adhesive matrix molecules (MSCRAMMS)
[6]. Each strain of S. aureus has its own ge-
netic repertoire of MSCRAMMS, yielding
strain-specific  adhesion  preferences  and
concomitant infection patterns. Once affixed
to a surface, S. aureus capitalizes on various
resources to evade the host immune system
in order to yield sufficient time for an infec-
tion to take hold. One such intriguing mech-
anism  is  the  formation  of  biofilms,
surface-associated bacterial collections sit-
uated within self-made extracellular poly-
meric  matrices  that  give  microbial
communities  protection  against  host  de-
fenses and antibiotics [7]. Scientific inquiry
into the genetic programs responsible for
biofilm formation has yielded insight into
the  development  of  adjunctive  therapies
[8,9]. 
When circumstances permit invasion
past physical host barriers, S. aureus deploys
several surface protein-based mechanisms to
survive in the midst of the host immune sys-
tem. Its antiphagocytic capsule provides the
primary mechanism against host phagocytic
immune cells, namely neutrophils, mono-
cytes, and macrophages [3]. Research also
has demonstrated that S. aureus uses bacte-
rial fibronectin-binding proteins (a type of
MSCRAMM) to evade host immune cell
phagocytosis. Specifically, to find refuge, it
creates a fibronectin bridge between the bac-
terium and host endothelial and epithelial
cell ß1 integrins, allowing for its internal-
ization and protection against extracellular
immune cells [10-12]. To further avoid anti-
body-mediated immunity, S. aureus utilizes
an additional surface protein virulence factor
called Protein A. In binding to the universal
Fc region of host immunoglobulins, Protein
A inhibits opsonization and phagocytosis
[3,13]. 
Secreted Proteins
S.  aureus employs  secreted  protein-
based mechanisms to defend itself from host
immune system phagocytosis. Greater than
one-half of S. aureus isolates secrete a sub-
stance called chemotaxis inhibitory protein
of S. aureus (CHIPS), which impairs neu-
trophil recruitment [3,14]. Isolates also can
produce  leukocidins,  factors  that  disrupt
leukocyte  membranes  by  creating  pores
[15]. Many other secreted factors, including
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Figure 2. Schematic diagram of S. aureus, depicting basic structure and a selection of vir-
ulence factors. Adapted from Gordon et al., 2008.lactamases,  proteases,  lipases,  nucleases,
hyaluronate  lyase,  phospholipase  C,  and
metalloproteinases also play a significant
role in infectious spread and tissue destruc-
tion [16].
Toxins
Numerous S. aureus isolates produce
toxins capable of causing specific physio-
logic disturbances. Toxins classified as su-
perantigens produce a cytokine storm and
provoke T cell proliferation. One such su-
perantigen, toxic shock syndrome toxin-1
(TSST-1), results in the clinically devastat-
ing toxic shock syndrome [17]. Exfoliative
toxins induce erythema as well as skin ex-
foliation, as is observed in the staphylococ-
cal scalded skin syndrome [18]. Finally, S.
aureus enterotoxin results in a self-limited
food poisoning [19].
In summary, in response to infection,
the host immune system readies for battle,
and its phagocytic immune cells are its in-
fantry. Many surface and secreted virulence
factors play major roles in both avoiding and
inhibiting  phagocyte-based  destruction.
Coupled with virulence factors that aid in
the disruption of tissue structure, S. aureus
affords itself the opportunity to disseminate
by reaching local lymphatics and blood ves-
sels [11]. S. aureus isolates also can produce
toxins, which, when present, are capable of
causing specific physiologic dysfunction. 
S. AureuS And diSeASe
The clinical presentation of S. aureus
infection is highly variable. It depends on
the clinical isolate’s complement of viru-
lence factors as well as the site and timing
of infection [11]. Skin infections are the
most frequently encountered S. aureus in-
fections. In the hospital setting, it is most
common to find S. aureus skin infections
postoperatively [11]. In the community, skin
infections include abscesses, bullous im-
petigo, folliculitis, furunculosis, and necro-
tizing fasciitis [20]. Clinically, in deciding
whether skin infection is the result of S. au-
reus, important clues are provided by the
skin distribution as well as the site of infec-
tion (e.g., facial, follicular, or deeper tissue)
[11]. If S. aureus penetrates the barrier af-
forded by the skin and successfully evades
the host immune system using the virulence
factor-based mechanisms discussed above,
it can disseminate, resulting in serious in-
fections, including sepsis, septic arthritis, os-
teomyelitis, and endocarditis [3]. 
The clinical management of localized S.
aureus skin infections is two-fold. First, the
correct type and form (intravenous, topical,
or oral) of antimicrobial therapy must be se-
lected. Second, infected abscesses must be
drained [11]. Severe and advanced infec-
tions require more significant and intensive
management in order to address limb-threat-
ening and/or life-threatening sequelae [21].
Several main principles govern the manage-
ment of such complicated cases [11,21]: 1)
diagnose and begin intravenous antimicro-
bial treatment early in the progression of the
disease; 2) differentiate between necrotizing
and non-necrotizing fasciitis; 3) identify re-
sistant profiles as well as virulence factors;
and 4) rapid surgical drainage and/or re-
moval of necrotic tissue. Toxin-mediated S.
aureus-related illnesses (e.g., toxic shock
syndrome and gastroenteritis) require symp-
tom-directed  management.  For  example,
treatment of toxic shock syndrome involves
fluid replacement and blood pressure sur-
veillance. In combating S. aureus toxins,
such as TSST-1, some studies have demon-
strated  the  utility  of  intravenous  im-
munoglobulin therapy [22,23]. 
AntiMicrobiAl tHerAPy: FroM
Penicillin to MetHicillin
In 1928, in his laboratory in London,
Scottish  biologist  and  pharmacologist
Alexander Fleming discovered that he had
left open the cover of a Petri dish containing
Staphylococcus, which had become con-
tained by a blue-green mold. To his amaze-
ment,  the  growth  of  the  Staphylococcus
adjacent to the mold was inhibited. Fleming
posited that the mold was secreting a sub-
stance that lysed its bacterial neighbors. It
was this discovery of a blue-green mold,
Penicillium notatum, and the resulting un-
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cillin, for which Fleming shared the 1945
Nobel  Prize  in  Physiology  or  Medicine
[24,25] (Figure 3).
The bacterial cell wall is important for
maintenance of cell shape and protection
against osmotic lysis. Therefore, pharmaco-
logic agents that disrupt this critical bacter-
ial component would likely be bactericidal.
Penicillin, a ß-lactam antibiotic, covalently
binds to and inhibits a collection of bacterial
proteins called penicillin binding proteins
(PBPs), which are responsible for the con-
struction, maintenance, and regulation of the
peptidoglycan portion of the cell wall [26].
S. aureus normally has four PBPs (PBP1-4);
PBP1, 2, and 3 are essential and exhibit high
affinity for ß-lactam antibiotics while PBP4
carries out secondary cross-linking of the
peptidoglycan [27,28].
Shortly after the introduction of peni-
cillin as a clinical therapeutic in the 1940s, a
strain  of  Staphylococcus  aureus rapidly
emerged  that  secreted  an  enzyme  called
penicillinase, which hydrolyzes penicillin
into inactive penicilloic acid. In the 1950s,
scientists at a United Kingdom-based phar-
maceutical company, Beecham, discovered
that placing bulky substituents on the peni-
cillin side chain would protect penicillins
from penicillinase-mediated destruction due
to steric hindrance. Subsequently, in 1959,
Beecham introduced methicillin, a class of
penicillinase resistant ß-lactams [29] (Fig-
ure  3).  Unfortunately,  however,  the  first
cases of methicillin-resistant S. aureus were
reported in Europe just a few years later
[30]. Then, less than a decade later, MRSA
was identified in the United States at Boston
City Hospital in almost 20 patients with ev-
idence of patient-to-patient spread [31]. 
MecHAniSMS oF S. AureuS
reSiStAnce to MetHicillin
In order to evade the bactericidal prop-
erties of methicillin, S. aureus has developed
several modes of resistance. Such mecha-
nisms include the expression of a methi-
cillin-hydrolyzing ß lactamase as well as the
expression of an altered form of PBP2 that
binds to methicillin with lower affinity and
with higher rates of methicillin release.
The most prevalent mode of methicillin
resistance in S. aureus, however, involves
the chromosomal presence of a large 40-60
kilobase stretch of foreign DNA called the
mec element. The mecA gene, nested within
the mec element, encodes for the 76 kDa
protein called PBP2a, a unique and newly
acquired PBP that exhibits a low affinity for
ß-lactam antibiotics. Therefore, when the
normal staphylococcal PBPs are inhibited
by ß-lactams, PBP2a can resume cell wall
assembly, enabling viability in the presence
of methicillin [24].
Data  suggests  that  mecA originated
from Staphylococcus sciuri, but the mecha-
nism by which this genomic transfer oc-
curred  remains  mysterious,  perhaps
involving recombinase proteins capable of
excising DNA from one place and integrat-
ing it into another [25,26]. Investigating the
clonality of 472 MRSA isolates using DNA
hybridization technology, Kreiswirth et al.
determined that this genetic relocation oc-
curred once and that all MRSA isolates are
descendants of this single clone [27].
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Figure 3. ß-lactam Antibiotics. Chemical
structure of (A) Penicillin and (B) Methicillin.
In (B), the left portion indicates modification
of the carbonyl group side chain of the
penicillin core that facilitates ￟-lactamase
resistance. ￟-lactam ring at the left in (A)
and middle in (B).Research  on  the  basic  properties  of
PBP2a has revealed novel targets for thera-
peutic intervention. Like other PBPs, PBP2a
catalyzes the formation of peptide crosslinks
(transpeptidation) between the gylcan chains
of the cell wall. However, PBP2a requires
atypical cell wall precursor molecules: a
pentaglycine-decorated side chain attached
to the position 3-L-lysine of the stem pep-
tide, as well as an amidated D-glutamine in
position 2. Construction of these peculiar
substrate molecules requires the assistance
of many accessory genes, including femABC
and fmhV, which are responsible for adding
these critical residues. Therefore, any thera-
peutic intervention that perturbs the function
of these accessory genes would diminish
methicillin resistance despite the continued
presence of PBP2a.
ß-lactam antibiotics effectively inhibit
the normal PBPs produced by S. aureus.
Therefore, therapeutics specifically targeted
against  PBP2a  would  be  of  great  utility
against MRSA. In 2002, Lim et al. solved
the crystal structure of a soluble derivative
of PBP2a, providing a detailed molecular
map of the active site cavity [32]. This crys-
tallographic  analysis  provides  important
clues for understanding how some ß-lactams
target PBP2a and for the rational design of
novel molecular therapies [33].
tHe SPreAd oF MrSA
MRSA is spreading and causing disease
at a rapid rate. Outbreaks have frequently
been reported in neonatal and surgical in-
tensive  care  units,  burn  units,  inpatient
wards, and operating rooms [34]. The pa-
tient-to-patient nosocomial transmission re-
sponsible for such outbreaks predominantly
occurs  through  the  hands  of  healthcare
workers [35]. The proportion of MRSA-re-
lated S. aureus infections in hospital inten-
sive care units has increased steadily from 2
percent in 1974 to 22 percent in 1995 and 64
percent in 2004 [36]. In 2005, 58 percent
(278,000) of hospitalizations that included a
diagnosis  of  S.  aureus were  caused  by
MRSA (including those admitted to the hos-
pital  for  community-acquired  infections)
[37]. According to a 2005 estimate, nearly
19,000 deaths were caused by MRSA [38].
Moreover, MRSA is now considered one of
the leading causes of death by any single in-
fectious pathogen [39]. MRSA, therefore,
has  expeditiously  become  a  significant
health burden to society.
Fortunately, major hospital efforts and
campaigns to reduce hospital-acquired in-
fections have helped diminish the incidence
of MRSA-related illness [40]. These efforts
include: 1) reduction in antibiotic use; 2)
healthcare worker education; 3) hand wash-
ing protocols and monitoring; 4) surveil-
lance cultures; and 5) isolation of patients
colonized with MRSA or perceived as a high
risk for infection [41]. Active surveillance
cultures and isolation protocols remain con-
troversial  as  some  studies  have  demon-
strated  the  lack  of  utility  in  employing
widespread screening efforts outside of the
intensive care units [41].
Hospital-based movements to reduce
the incidence of MRSA have undoubtedly
demonstrated success. Between 2001 and
2007, MRSA central line-associated blood-
stream infections within intensive care units
have decreased by nearly 50 percent [42].
Similarly, a separate study that investigated
hospitalized  patients  between  2005  and
2008 demonstrated a 34 percent reduction in
the incidence of MRSA-related bloodstream
infections [40]. Continued efforts must be
exercised to prevent the spread of MRSA in
the hospital setting. New strategies may in-
clude attempts to minimize the length of
hospital  stay  and  improved  surveillance
techniques, as well as more strict hand hy-
giene regulations [35].
FroM tHe HoSPitAl to tHe 
coMMunity
While MRSA was once just a hospital-
acquired  infection  observed  in  immuno-
compromised hosts, the rapid and persistent
emergence of community-associated MRSA
(CA-MRSA) has caused considerable con-
cern. Illustrative of its means to quickly dis-
seminate  through  populations  is  its
pervasive international presence and its abil-
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The medical community recognized the first
cases of CA-MRSA in the 1990s, first in re-
mote Western Australia [44] and then with a
group of otherwise healthy children in the
Midwestern United States [45]. None of the
affected individuals had contact with the
healthcare setting or exhibited any identified
risk factors prior to infection. The ability of
CA-MRSA  to  cause  disease  in  immuno-
competent healthy hosts suggests that CA-
MRSA  harbors  novel  mechanisms  of
virulence  [39].  Genetic  analyses  of  CA-
MRSA isolates support this assertion, as
several isolates harbor a unique mec element
as  well  as  express  the  Panton-Valentine
leukocidin (PVL), a factor linked to severe
skin infections in the community [3,46].
Given that nearly 90 percent of CA-MRSA
cases are skin and soft tissue infections, 90
percent of which are abscesses or cellulitis
[39], it is likely that PVL plays a significant
role in the pathogenesis of CA-MRSA. Fu-
ture concern and attention is certainly war-
ranted.  The  presence  of  severe
community-acquired infections such as pur-
pura fulminans, myositis, osteomyolitis, and
necrotizing fasciitis suggests the potential
for increased virulence [39]. 
The emergence of CA-MRSA as a grow-
ing threat has posed new preventive and ther-
apeutic challenges. Akin to hospital-acquired
MRSA, the community variant demonstrates
extensive resistance to ß-lactam antibiotics.
Currently, little clinical evidence exists re-
garding  the  efficacy  of  alternative  agents.
Thus, most non-invasive CA-MRSA skin in-
fections are not treated with antibiotics. In-
stead, abscesses are simply drained [39]. If
antibiotics are indicated as the result of more
significant signs of infection, clindamycin,
tetracyclines (including doxycyline), trimetho-
prim-sulfamethoxazole, and linezolid are the
drugs of choice [47]. More severe cases of CA-
MRSA  are  treated  with  parenteral  van-
comycin, daptomycin, teicoplanin, or linezolid
[48].
tHe Antibiotic PiPeline
The Centers for Disease Control (CDC)
estimates that roughly two million people in
the United States will develop bacterial in-
fections while in the hospital and that nearly
90,000 will die from associated complica-
tions. Close to 70 percent of the bacteria re-
sponsible  for  these  infections  will  be
resistant to at least one commonly used an-
tibiotic. In recent decades, antibiotic resist-
ant organisms have spread at alarming rates,
causing the Institute of Medicine, CDC, Na-
tional Institutes of Health, and the Food and
Drug Administration (FDA) to caution that
drug-resistant organisms pose a serious pub-
lic health concern [49].
Given the rapid spread of drug-resistant
bacteria, one might suspect that the pharma-
ceutical and biotechnology industries would
be countering with an equally impressive
course of antimicrobial development. How-
ever, the spread of drug-resistant organisms
has largely outpaced antibiotic research and
development. In fact, in comparing the peri-
ods of 1998 to 2002 and 1983 to 1987, FDA
approval of new antibiotics decreased 56
percent, with no new antibacterial agents ap-
proved in 2002. A startling downward trend
emerges  when  examining  the  number  of
new systemic antibiotics approved by the
FDA over the last 25 years [50] (Figure 4).
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Figure 4. Number of new antimicrobials ap-
proved by the U.S. Food and Drug Adminis-
tration, per five-year period. Adapted from
Spellberg et al., 2008.Many reasons could explain the paucity
of research and development in antimicro-
bial therapeutics, most of which point to fi-
nancial  considerations.  Two  independent
studies from 2001 and 2003 estimate that the
cost of discovering and then developing a
new drug in the United States exceeds $800
million [51,52]. This figure presents a sig-
nificant investment challenge for the devel-
opment  of  drugs  targeted  against  short
course therapies that cure their target dis-
ease, leaving most of drug discovery fo-
cused  on  chronic  lifelong  non-curative
diseases. A further impediment to ongoing
development is that antibiotics are the only
class of drugs whose effectiveness decreases
the more they are employed, which causes
leaders to advocate for restrictions on and
judicial use of new antimicrobial therapies.
Lastly, the pharmaceutical industry cites the
lack of clear guidance from regulatory agen-
cies as a deterrent for ongoing antibiotic de-
velopment. They express uncertainty about
what types of safety and efficacy data will
be deemed appropriate at the time of formal
drug application [53].
In response to the pervasive problem of
drug-resistant organisms coupled with a lim-
ited developmental pipeline for drug dis-
covery, the Infectious Diseases Society of
America (IDSA), with the broad support of
leading medical societies and organizations,
has launched the 10x‘20 initiative. The bold
aim of this collaboration between scientific,
industry, political, economic, policy, med-
ical, intellectual property, and philanthropic
leaders is the development of 10 new, safe,
and effective antibiotics by 2020. To do this,
the 10x‘20 initiative advocates for the de-
velopment  of  new  systemic  antibacterial
therapeutics not only through the discovery
of new drug classes, but also through the
evolution of more effective drugs from ex-
isting classes of antibiotics. Global stake-
holders recognize the imminent need for
antimicrobial development. With the IDSA’s
support,  in  2009,  U.S.  President  Barack
Obama and Swedish Prime Minister Fredrik
Reinfeldt, acting on behalf of the European
Union, created a transatlantic task force to
focus on solutions to the dwindling antibi-
otic pipeline and find ways to fortify infec-
tion control interventions and practices [54].
tHe SeArcH For noVel 
AntibioticS
While the impending crisis has wors-
ened over the past decade, academic and
biotechnology companies have made signif-
icant and noteworthy progress toward de-
velopment  of  effective  antimicrobial
therapeutics. One such example is the re-
search of Dr. Andrew G. Myers of the De-
partment  of  Chemistry  and  Chemical
Biology  at  Harvard  University,  who  re-
vealed a novel route and robust platform for
the synthesis of new tetracycline antibiotics
[55,56]. Tetraphase Pharmaceuticals, a com-
pany based on this research, already has de-
veloped a cadre of drug candidates with the
potential to treat a wide range of infectious
diseases. Moreover, a lead drug candidate
called TP-434 has shown great preclinical
promise as a potent antibacterial against a
broad  spectrum  of  susceptible  and  mul-
tidrug-resistant organisms [57].
The Nobel Prize for Chemistry in 2009
highlights  a  seminal  scientific  discovery
holding immense relevance to antimicrobial
therapeutic development. Drs. Ada Yonath
(Israel), Thomas Steitz (United States), and
Venki  Ramakrishnan  (United  Kingdom)
were awarded the Nobel Prize for elucidat-
ing the atomic three-dimensional structure
of the ribosome using X-ray crystallography,
the  machine  within  cells  responsible  for
making proteins and the target of many of
today’s antimicrobial agents. In pioneering
work, Dr. Steitz, a Sterling Professor of Mo-
lecular Biophysics and Biochemistry and
Howard Hughes Medical Institute Investi-
gator  at  Yale  University,  and  colleagues
demonstrated the structural basis of bacter-
ial resistance to clinically important antibi-
otics, revealing important insights into novel
antibiotic development [58]. Based on these
important observations, Dr. Steitz and his
colleagues have founded Rib-X Pharmaceu-
ticals [59]. Rib-X is developing a novel class
of broad-spectrum antibitiocs called RX-04.
In  addition,  delafloxaxin,  Rib-X’s  novel
230 Morell and Balkin: MRSA highlights need for antimicrobial developmentfluroquinolone antibiotic, has successfully
completed three Phase 2 clinical studies and
demonstrated  utility  in  the  fight  against
MRSA [60].
concluSion And outlooK
Without a doubt, the medical commu-
nity is now astutely aware of the global bur-
den of disease imposed by drug-resistant S.
aureus infections. The ubiquitous knowl-
edge of MRSA in communities is evident by
its common use as a new household term.
The consequences of the MRSA pandemic
are profound and worrisome. MRSA itself is
only a symptom of a broader phenomenon,
a harbinger of a growing pool of resistant
pathogens found both in hospitals and in the
community. While researchers, both aca-
demic and pharmaceutical, are working to
develop therapeutic responses and have al-
ready have made significant advances, con-
siderable  work  remains.  The  continued
emergence of resistant strains of bacteria
such as MRSA demands an urgent response.
An efficient, comprehensive, multidiscipli-
nary search for new antibiotics must com-
mence to prepare us to squelch strains of
resistant pathogens as they inevitably strike.
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